Health&Beauty- Page 76

The FINANCIAL -- A 20-year rise in cardiovascular disease (CVD) in China appears to have been spurred largely by increases in high blood pressure, according to a new study from Harvard T.H. Chan School of Public Health. Increasing body mass index (BMI),

The FINANCIAL -- After more than two years without wild poliovirus in Nigeria, the Government reported on August 11 that 2 children have been paralyzed by the disease in the northern Borno state.

The FINANCIAL -- Some bacteria, called fusobacteria, commonly found in the mouth, use a sugar-binding protein to stick to developing colorectal polyps and cancers, according to a new study by researchers from Harvard T.H. Chan School of Public Health and Hebrew University-Hadassah

The FINANCIAL -- Every year, around eight million babies are affected by birth defects globally. These include life-debilitating neural tube defects (NTDs) which result in devastating conditions such as anencephaly, an absence of major parts of the brain, and spina bifida, an

The FINANCIAL -- Levels of a widely used class of industrial chemicals linked with cancer and other health problems—polyfluoroalkyl and perfluoroalkyl substances (PFASs)—exceed federally recommended safety levels in public drinking water supplies for six million people in the U.S., according to a

The FINANCIAL -- The University of Liverpool is running the largest ever investigation into artificially sweetened drinks and their effect on weight loss and weight maintenance.

The FINANCIAL -- The percentage of smokers in the U.S. who light up a pack or more of cigarettes a day has fallen sharply over the past decade and is now at an all-time low of 26% in Gallup's seven-decade trend. The

The FINANCIAL -- A major clinical trial involving patients with obesity and type 2 diabetes, led by researchers from across the University of Liverpool has been funded £1 million.

The FINANCIAL -- Scientists from the University of Liverpool and Victoria University of Wellington have been awarded over £478K to advance a potential treatment for Alzheimer’s disease.

The FINANCIAL -- Bristol-Myers Squibb Company today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in